{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:01:48Z","timestamp":1778814108810,"version":"3.51.4"},"reference-count":37,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6,27]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>EPCR levels influence the hemostatic effect of rFVIIa in hemophilia therapy. FVIIa binding to EPCR influences the hemostatic effect of FVIIa because of downregulation of protein C anticoagulation pathway.<\/jats:p>","DOI":"10.1182\/bloodadvances.2016004143","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:30:19Z","timestamp":1498609819000},"page":"1206-1214","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action"],"prefix":"10.1182","volume":"1","author":[{"given":"Shiva","family":"Keshava","sequence":"first","affiliation":[{"name":"Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagan","family":"Sundaram","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Rajulapati","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles T.","family":"Esmon","sequence":"additional","affiliation":[{"name":"Coagulation Biology Laboratory, Oklahoma Medical Research Foundation, Oklahoma City, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha R.","family":"Pendurthi","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2099-0585","authenticated-orcid":false,"given":"L. Vijaya Mohan","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2017,6,27]]},"reference":[{"issue":"16","key":"2019111607210017700_B1","doi-asserted-by":"crossref","first-page":"11849","DOI":"10.1074\/jbc.M609283200","article-title":"Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium","volume":"282","author":"Ghosh","year":"2007","journal-title":"J Biol Chem"},{"issue":"39","key":"2019111607210017700_B2","doi-asserted-by":"crossref","first-page":"28850","DOI":"10.1074\/jbc.M604966200","article-title":"Multifunctional specificity of the protein C\/activated protein C Gla domain","volume":"281","author":"Preston","year":"2006","journal-title":"J Biol Chem"},{"issue":"9","key":"2019111607210017700_B3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1538-7836.2007.02648.x","article-title":"Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity","volume":"5","author":"L\u00f3pez-Sagaseta","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111607210017700_B4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0038-1642646","article-title":"The tissue factor pathway: how it has become a \u201cprima ballerina.\u201d","volume":"74","author":"Rapaport","year":"1995","journal-title":"Thromb Haemost"},{"issue":"10","key":"2019111607210017700_B5","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-05-578328","article-title":"Endothelial cell protein C receptor: a multiliganded and multifunctional receptor","volume":"124","author":"Mohan Rao","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019111607210017700_B6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0037-1613883","article-title":"The endothelial cell protein C receptor","volume":"83","author":"Esmon","year":"2000","journal-title":"Thromb Haemost"},{"issue":"19","key":"2019111607210017700_B7","doi-asserted-by":"crossref","first-page":"10212","DOI":"10.1073\/pnas.93.19.10212","article-title":"The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex","volume":"93","author":"Stearns-Kurosawa","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2019111607210017700_B8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1160\/TH11-09-0672","article-title":"Factor VIIa binding to endothelial cell protein C receptor: differences between mouse and human systems","volume":"107","author":"Sen","year":"2012","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111607210017700_B9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jbiotec.2006.03.042","article-title":"Mechanism of action, development and clinical experience of recombinant FVIIa","volume":"124","author":"Hedner","year":"2006","journal-title":"J Biotechnol"},{"issue":"Suppl 1","key":"2019111607210017700_B10","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0268-960X(15)30002-3","article-title":"Recombinant activated factor VII: 30 years of research and innovation","volume":"29","author":"Hedner","year":"2015","journal-title":"Blood Rev"},{"issue":"2 Suppl 1","key":"2019111607210017700_B11","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1053\/j.seminhematol.2008.03.013","article-title":"Further understanding of recombinant activated factor VII mode of action","volume":"45","author":"Monroe","year":"2008","journal-title":"Semin Hematol"},{"issue":"5","key":"2019111607210017700_B12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1055\/s-0030-1255442","article-title":"Recombinant activated factor VII: mechanisms of action and current indications","volume":"36","author":"Franchini","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"2019111607210017700_B13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jth.13244","article-title":"Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice","volume":"14","author":"Keshava","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019111607210017700_B14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood-2014-04-567297","article-title":"The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo","volume":"124","author":"Pavani","year":"2014","journal-title":"Blood"},{"issue":"18","key":"2019111607210017700_B15","doi-asserted-by":"crossref","first-page":"11863","DOI":"10.1074\/jbc.272.18.11863","article-title":"Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor","volume":"272","author":"Sorensen","year":"1997","journal-title":"J Biol Chem"},{"issue":"7","key":"2019111607210017700_B16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1538-7836.2005.01385.x","article-title":"Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin","volume":"3","author":"Li","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2019111607210017700_B17","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1182\/blood-2005-01-0406","article-title":"Extraembryonic expression of EPCR is essential for embryonic viability","volume":"106","author":"Li","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2019111607210017700_B18","doi-asserted-by":"crossref","first-page":"e103505","DOI":"10.1371\/journal.pone.0103505","article-title":"Inactivation of factor VIIa by antithrombin in vitro, ex vivo and in vivo: role of tissue factor and endothelial cell protein C receptor","volume":"9","author":"Vatsyayan","year":"2014","journal-title":"PLoS One"},{"issue":"19","key":"2019111607210017700_B19","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2014-09-600254","article-title":"Blockade of endothelial cell protein C receptor augments factor VIIa hemostatic effect in hemophilia treatment","volume":"124","author":"Sundaram","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111607210017700_B20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jth.13607","article-title":"One amino acid in mouse activated factor VII defines its endothelial protein C receptor (EPCR) binding and modulates its EPCR-dependent hemostatic activity in vivo","volume":"15","author":"Pavani","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111607210017700_B21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC-specific serpin for the treatment of hemophilia","volume":"129","author":"Polderdijk","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2019111607210017700_B22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1160\/th15-07-0525","article-title":"Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa","volume":"115","author":"Bhat","year":"2016","journal-title":"Thromb Haemost"},{"issue":"22","key":"2019111607210017700_B23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood.V128.22.80.80","article-title":"Targeted inhibition of activated protein C anticoagulant activity by monoclonal antibody HAPC1573 for treatment of hemophilia [abstract]","volume":"128","author":"Zhao","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111607210017700_B24","first-page":"219","article-title":"Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man","volume":"50","author":"Freireich","year":"1966","journal-title":"Cancer Chemother Rep"},{"issue":"2","key":"2019111607210017700_B25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"2019111607210017700_B26","unstructured":"US Food and Drug Administration. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005. Rockville, MD. Available at: https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm078932.pdf. Accessed 8 June 2017."},{"issue":"5","key":"2019111607210017700_B27","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1067\/mva.2001.112808","article-title":"Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury","volume":"33","author":"S\u00f6derstr\u00f6m","year":"2001","journal-title":"J Vasc Surg"},{"issue":"1","key":"2019111607210017700_B28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/01.RES.82.1.39","article-title":"Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis","volume":"82","author":"Golino","year":"1998","journal-title":"Circ Res"},{"issue":"1","key":"2019111607210017700_B29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.00547.x","article-title":"Characterization of a tissue factor\/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits","volume":"2","author":"Chi","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2019111607210017700_B30","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood-2013-08-522987","article-title":"FVIIa as used pharmacologically is not TF dependent in hemophilia B mice","volume":"123","author":"Feng","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111607210017700_B31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","article-title":"Platelet activity of high-dose factor VIIa is independent of tissue factor","volume":"99","author":"Monroe","year":"1997","journal-title":"Br J Haematol"},{"issue":"4 Suppl 12","key":"2019111607210017700_B32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0037-1963(01)90140-4","article-title":"The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis","volume":"38","author":"Hoffman","year":"2001","journal-title":"Semin Hematol"},{"issue":"4","key":"2019111607210017700_B33","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2011.04223.x","article-title":"Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity","volume":"9","author":"Hoffman","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2019111607210017700_B34","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1161\/01.CIR.96.10.3633","article-title":"Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway","volume":"96","author":"Laszik","year":"1997","journal-title":"Circulation"},{"issue":"3","key":"2019111607210017700_B35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1006\/bbrc.1999.0846","article-title":"The endothelial cell protein C receptor (EPCR) functions as a primary receptor for protein C activation on endothelial cells in arteries, veins, and capillaries","volume":"259","author":"Ye","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"2019111607210017700_B36","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1182\/blood-2010-09-310706","article-title":"Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection","volume":"117","author":"Sen","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111607210017700_B37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/jth.12532","article-title":"Factor VIIa binding to endothelial cell protein C receptor protects vascular barrier integrity in vivo","volume":"12","author":"Sundaram","year":"2014","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/15\/1206\/878706\/advances004143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/15\/1206\/878706\/advances004143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T00:50:36Z","timestamp":1602377436000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/15\/1206\/15751\/Factor-VIIa-interaction-with-EPCR-modulates-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,27]]},"references-count":37,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,6,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2016004143","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,27]]}}}